$599

Pfizer FY 2026 Investor Call; Kailera Initiates Ph3 Obesity Program; Noom Biomarker Partnership; GLP-1RA Retinopathy Lawsuits

A series of cardiometabolic-related news items has been observed from Pfizer, Kailera Therapeutics, Noom, and the US Judicial Panel. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here